11,095 Shares in AxoGen, Inc. (NASDAQ:AXGN) Purchased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. purchased a new position in AxoGen, Inc. (NASDAQ:AXGN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 11,095 shares of the medical equipment provider’s stock, valued at approximately $156,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Sentry Investment Management LLC grew its position in AxoGen by 9.3% in the third quarter. Sentry Investment Management LLC now owns 17,368 shares of the medical equipment provider’s stock worth $243,000 after acquiring an additional 1,483 shares in the last quarter. BNP Paribas Financial Markets grew its position in AxoGen by 8.6% in the first quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock worth $168,000 after acquiring an additional 1,651 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in AxoGen by 8.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider’s stock worth $240,000 after acquiring an additional 2,204 shares in the last quarter. Lazard Asset Management LLC grew its position in AxoGen by 30.1% in the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock worth $93,000 after acquiring an additional 2,671 shares in the last quarter. Finally, Rhumbline Advisers grew its position in AxoGen by 6.2% in the second quarter. Rhumbline Advisers now owns 58,157 shares of the medical equipment provider’s stock worth $421,000 after acquiring an additional 3,380 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

AxoGen Price Performance

Shares of AXGN stock opened at $13.34 on Friday. AxoGen, Inc. has a 52-week low of $5.55 and a 52-week high of $15.90. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The firm has a market capitalization of $587.09 million, a P/E ratio of -41.69 and a beta of 1.13. The stock has a 50 day moving average price of $13.75 and a 200 day moving average price of $10.60.

Wall Street Analyst Weigh In

Several research analysts recently commented on AXGN shares. JMP Securities lifted their price target on AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Friday, August 9th. StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $15.00.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.